Market Summary
USD103.53-3.21
Market Closed-3.01%
MRNA Stock Price
MRNA RSI Chart
MRNA Valuation
MRNA Price/Sales (Trailing)
MRNA Profitability
MRNA Fundamentals
MRNA Revenue
MRNA Earnings
Price Action
52 Week Range
95.02217.25
(Low)(High)
Last 7 days
-4.7%
Last 30 days
-6.8%
Last 90 days
-14.1%
Trailing 12 Months
-20.2%
MRNA Financial Health
MRNA Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for MRNA
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-15 | Hoge Stephen | sold | -1,694,850 | 112 | -15,000 | president |
2023-09-15 | Bancel Stephane | acquired | - | - | 17,893 | chief executive officer |
2023-09-13 | AFEYAN NOUBAR | sold | -1,645,520 | 109 | -15,000 | - |
2023-09-08 | Klinger Shannon Thyme | sold | -59,722 | 107 | -557 | chief legal officer |
2023-09-07 | Klinger Shannon Thyme | acquired | - | - | 1,138 | chief legal officer |
2023-09-06 | Garay Arpa | sold | -62,219 | 108 | -574 | chief commercial officer |
2023-09-06 | AFEYAN NOUBAR | sold | -1,614,090 | 107 | -15,000 | - |
2023-09-05 | Klinger Shannon Thyme | sold | -12,815 | 111 | -115 | chief legal officer |
2023-09-05 | Hoge Stephen | sold | -35,659 | 111 | -320 | president |
2023-09-05 | Garay Arpa | acquired | - | - | 1,140 | chief commercial officer |
Which funds bought or sold MRNA recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-14 | IMS Capital Management | sold off | -100 | -1,203,150 | - | -% |
2023-09-12 | Farther Finance Advisors, LLC | added | 22.81 | -498 | 17,010 | -% |
2023-09-07 | Triatomic Management LP | added | 19.32 | -37,877 | 637,875 | 0.65% |
2023-09-05 | Delos Wealth Advisors, LLC | unchanged | - | -32.00 | 122 | -% |
2023-09-01 | Manhattan West Asset Management, LLC | added | 116 | 607,201 | 1,454,960 | 0.54% |
2023-08-24 | Alberta Investment Management Corp | unchanged | - | -2,817,430 | 10,670,700 | 0.10% |
2023-08-23 | Stonebridge Capital Advisors LLC | unchanged | - | -7,859 | 29,768 | -% |
2023-08-23 | WOLVERINE TRADING, LLC | added | 635 | 2,608,890 | 3,120,890 | -% |
2023-08-22 | Asset Dedication, LLC | unchanged | - | -23,000 | 87,000 | 0.01% |
2023-08-22 | COMERICA BANK | new | - | 29,000 | 29,000 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Moderna
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 7.10% | 27,282,173 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 6.8% | 26,115,224 | SC 13G/A | |
| Jan 19, 2023 | baillie gifford & co | 11.66% | 44,786,746 | SC 13G/A | |
| Feb 14, 2022 | bancel stephane | 7.64% | 31,538,184 | SC 13G/A | |
| Feb 14, 2022 | flagship ventures fund iv general partner llc | 2.8% | 11,460,435 | SC 13G/A | |
| Feb 04, 2022 | blackrock inc. | 6.8% | 27,661,473 | SC 13G | |
| Jan 26, 2022 | baillie gifford & co | 11.29% | 45,772,079 | SC 13G/A | |
| Jul 12, 2021 | blackrock inc. | 4.8% | 19,390,725 | SC 13G/A | |
| Mar 01, 2021 | baillie gifford & co | 11.18% | 44,691,386 | SC 13G/A | |
| Feb 16, 2021 | flagship ventures fund iv general partner llc | 2.9% | 11,460,435 | SC 13G/A |
Recent SEC filings of Moderna
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 20, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 18, 2023 | 4 | Insider Trading | |
| Sep 15, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 15, 2023 | 4 | Insider Trading | |
| Sep 15, 2023 | 4 | Insider Trading | |
| Sep 13, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 8-K | Current Report | |
| Sep 08, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 08, 2023 | 4 | Insider Trading |
Peers (Alternatives to Moderna)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 145.2B | 26.6B | 4.13% | 21.09% | 18.2 | 5.46 | 0.75% | 21.34% |
GILD | 94.5B | 27.4B | -0.16% | 19.51% | 17.24 | 3.45 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -6.80% | -20.18% | 32.68 | 3.7 | -53.67% | -91.41% |
BIIB | 37.7B | 10.0B | -1.71% | 27.59% | 14.15 | 3.78 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.2B | 1.7B | 5.59% | 6.81% | 63.29 | 6.67 | 29.01% | 1345.90% |
BBIO | 4.5B | - | -3.04% | 140.92% | -7.66 | 48.33 | 54.84% | -12.96% |
DNLI | 3.1B | - | -4.51% | -22.98% | -23.78 | 37.44 | 122.90% | 54.78% |
BEAM | 2.0B | 80.2M | 6.46% | -52.82% | -6.01 | 24.54 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.5B | 121.2M | 4.38% | -25.42% | -5.13 | 12.17 | -70.36% | -531.73% |
REPL | 980.2M | 15.3M | -15.63% | 3.04% | -5.4 | 64.02 | 1090.59% | -36.57% |
NVAX | 664.9M | 1.6B | -12.64% | -74.33% | -1.13 | 0.42 | 23.74% | 60.24% |
FATE | 221.7M | - | -17.58% | -90.72% | -1.05 | 1.62 | 116.83% | 16.61% |
SGMO | 146.7M | - | -8.84% | -84.12% | -0.74 | 0.61 | 113.96% | -15.19% |
VXRT | 112.7M | 2.1M | -6.14% | -67.90% | -1.12 | 54.83 | 487.70% | -8.66% |
IBIO | 4.1M | - | -12.28% | -96.10% | -0.05 | 3.21 | - | -129.46% |
Moderna News
Returns for MRNA
Cumulative Returns on MRNA
14.0%
3-Year Cumulative Returns
Risks for MRNA
What is the probability of a big loss on MRNA?
99.2%
Probability that Moderna stock will be more than 20% underwater in next one year
83.4%
Probability that Moderna stock will be more than 30% underwater in next one year.
49.4%
Probability that Moderna stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does MRNA drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Moderna was unfortunately bought at previous high price.
Drawdowns
Financials for Moderna
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -29.3% | 10,654,000,000 | 15,059,000,000 | 19,263,000,000 | 21,390,000,000 | 22,995,000,000 | 22,600,000,000 | 18,471,000,000 | 11,831,000,000 | 7,019,000,000 | 2,732,000,000 | 803,000,000 | 246,055,000 | 106,101,000 | 52,184,000 | 60,209,000 | 81,575,000 | 106,286,000 | 122,054,000 | 135,068,000 | 191,551,000 | 192,266,000 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 865,367,000 | 620,150,000 | 588,464,000 | 606,879,000 | 650,720,000 | 630,485,000 | 599,559,000 | 548,334,000 | 493,614,000 | 476,382,000 |
| S&GA Expenses | 10.4% | 1,290,000,000 | 1,169,000,000 | 1,132,000,000 | 958,000,000 | 848,000,000 | 758,000,000 | 567,000,000 | 445,000,000 | 325,000,000 | 241,000,000 | 188,000,000 | 135,087,000 | 115,260,000 | 106,747,000 | 110,000,000 | 121,936,000 | 112,288,000 | 105,188,000 | 94,252,000 | 74,972,000 | 75,408,000 |
| R&D Expenses | 11.3% | 4,310,000,000 | 3,872,000,000 | 3,295,000,000 | 2,732,000,000 | 2,433,000,000 | 2,144,000,000 | 1,991,000,000 | 2,102,000,000 | 1,925,000,000 | 1,656,000,000 | 1,370,000,000 | 728,645,000 | 504,282,000 | 480,587,000 | 496,000,000 | 528,784,000 | 518,197,000 | 494,371,000 | 454,082,000 | 404,870,667 | 389,206,000 |
| EBITDA | -100.0% | - | 5,413,000,000 | 9,948,000,000 | - | 15,968,000,000 | 16,564,000,000 | 13,531,000,000 | - | - | 687,063,000 | -704,472,000 | -563,923,000 | -456,516,000 | -475,315,000 | -484,000,000 | -500,148,000 | -457,886,000 | -414,665,000 | - | - | - |
| EBITDA Margin | -100.0% | - | 0.36 | 0.52 | - | 0.69 | 0.73 | 0.73 | - | - | 0.25 | -0.88 | -2.29 | -4.31 | -9.04 | -8.04 | -6.13 | -4.31 | -3.40 | - | - | - |
| Interest Expenses | - | - | - | 25,000,000 | - | - | - | 14,000,000 | - | - | - | 9,000,000 | - | - | - | 6,000,000 | - | - | - | 2,998,000 | - | - |
| Earnings Before Taxes | -83.8% | 818,000,000 | 5,041,000,000 | 9,575,000,000 | 13,330,000,000 | 15,665,000,000 | 16,254,000,000 | 13,285,000,000 | 7,604,000,000 | 3,820,000,000 | 640,000,000 | -744,000,000 | -596,743,000 | -488,136,000 | -506,400,000 | -515,000,000 | -532,515,000 | -489,453,000 | -444,632,000 | -384,408,000 | -324,200,000 | -325,638,000 |
| EBT Margin | -100.0% | - | 0.33 | 0.50 | 0.62 | 0.68 | 0.72 | 0.72 | 0.64 | 0.54 | 0.23 | -0.93 | -2.42 | -4.61 | -9.64 | -8.55 | - | - | - | - | - | - |
| Net Income | -74.8% | 1,207,000,000 | 4,784,000,000 | 8,362,000,000 | 11,765,000,000 | 14,055,000,000 | 14,638,000,000 | 12,202,000,000 | 7,061,000,000 | 3,495,000,000 | 598,000,000 | -747,000,000 | -597,269,000 | -487,484,000 | -505,424,000 | -514,000,000 | -532,157,000 | -489,273,000 | -444,934,000 | -384,734,000 | -324,410,666 | -325,954,000 |
| Net Income Margin | -100.0% | - | 0.32 | 0.43 | 0.55 | 0.61 | 0.65 | 0.66 | 0.60 | 0.50 | 0.22 | -0.93 | -2.42 | -4.61 | -9.62 | -8.54 | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 612,000,000 | 4,581,000,000 | 6,201,000,000 | 9,215,000,000 | 13,031,000,000 | 13,336,000,000 | 11,386,436,000 | 9,083,037,000 | 5,007,746,000 | 1,959,523,000 | 613,169,000 | -371,194,000 | -451,223,000 | -490,522,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2017Q4 |
| Assets | -9.3% | 21,884 | 24,125 | 25,858 | 26,056 | 26,043 | 27,609 | 24,669 | 20,923 | 16,153 | 12,694 | 7,337 | 4,651 | 3,486 | 2,068 | 1,589 | 1,591 | 1,685 | 1,806 | 1,962 | 1,084 |
| Current Assets | -12.6% | 10,599 | 12,122 | 13,431 | 14,297 | 13,563 | 16,350 | 16,071 | 13,425 | 10,969 | 11,703 | 6,298 | 3,577 | 2,797 | 1,250 | 1,129 | 1,094 | 1,097 | 1,141 | 1,563 | 783 |
| Cash Equivalents | 10.5% | 3,801 | 3,441 | 3,205 | 3,027 | 2,873 | 5,048 | 6,860 | 5,550 | 5,603 | 5,442 | 2,624 | 1,506 | 1,762 | 392 | 248 | 174 | 152 | 503 | 670 | 148 |
| Inventory | -2.3% | 715 | 732 | 949 | 2,077 | 1,921 | 1,942 | 1,441 | 965 | 643 | 494 | 47.00 | - | - | - | - | - | - | - | - | - |
| Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 204 | 209 | 213 | 212 | 139 |
| Liabilities | -6.2% | 4,935 | 5,262 | 6,735 | 8,064 | 8,058 | 10,534 | 10,524 | 10,799 | 9,449 | 8,856 | 4,776 | 1,891 | 539 | 427 | 415 | 339 | 347 | 360 | 432 | 459 |
| Current Liabilities | -10.7% | 3,123 | 3,499 | 4,923 | 6,807 | 6,812 | 9,238 | 9,128 | 9,957 | 8,840 | 8,441 | 4,389 | 1,474 | 162 | 135 | 143 | 148 | 162 | 159 | 223 | 191 |
| Shareholder's Equity | -10.1% | 16,949 | 18,863 | 19,123 | 17,992 | 17,985 | 17,075 | 14,145 | 10,124 | 6,704 | 3,838 | 2,561 | 2,760 | 2,947 | 1,641 | 1,175 | 1,248 | 1,335 | 1,442 | 1,530 | - |
| Retained Earnings | -7.5% | 17,019 | 18,399 | 18,320 | 16,855 | 15,812 | 13,615 | 9,958 | 5,090 | 1,757 | -1,023 | -2,244 | -1,970 | -1,740 | -1,620 | -1,496 | -1,369 | -1,246 | -1,111 | -982 | -621 |
| Additional Paid-In Capital | -73.6% | 193 | 731 | 1,173 | 1,488 | 2,413 | 3,644 | 4,211 | 5,003 | 4,931 | 4,860 | 4,802 | 4,726 | 4,676 | 3,268 | 2,669 | 2,618 | 2,582 | 2,557 | 2,538 | 72.00 |
| Shares Outstanding | -0.8% | 381 | 384 | 385 | 387 | 396 | 402 | 403 | 404 | 402 | 400 | 399 | 395 | 381 | 353 | 337 | 331 | 329 | 329 | 81.00 | 64.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -122.8% | -226 | 993 | 4,981 | 6,629 | 9,653 | 13,412 | 13,620 | 11,574 | 9,191 | 5,104 | 2,027 | 664 | -336 | -420 | -459 | -450 | -424 | -363 | -330 | -319 | -319 |
| Share Based Compensation | 9.3% | 281 | 257 | 226 | 201 | 171 | 156 | 142 | 131 | 113 | 103 | 93.00 | 87.00 | 86.00 | 83.00 | 81.00 | 92.00 | 86.00 | 79.00 | 73.00 | 55.00 | 52.00 |
| Cashflow From Investing | 409.5% | 3,852 | 756 | -5,176 | -5,266 | -9,538 | -12,264 | -8,523 | -7,575 | -5,427 | -1,536 | -1,672 | -1,351 | -59.34 | -319 | -15.00 | -139 | -136 | 99.00 | -373 | -505 | -990 |
| Cashflow From Financing | 19.7% | -2,689 | -3,348 | -3,448 | -3,883 | -2,844 | -1,541 | -873 | 44.00 | 76.00 | 1,481 | 2,033 | 2,021 | 2,007 | 630 | 52.00 | 596 | 571 | 677 | 1,227 | 868 | 1,321 |
| Buy Backs | -20.7% | 2,562 | 3,232 | 3,329 | 3,784 | 2,778 | 1,480 | 857 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
MRNA Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Total revenue | $ 344 | $ 4,749 | $ 2,206 | $ 10,815 |
| Operating expenses: | ||||
| Cost of sales | 731 | 1,381 | 1,523 | 2,398 |
| Research and development | 1,148 | 710 | 2,279 | 1,264 |
| Selling, general and administrative | 332 | 211 | 637 | 479 |
| Total operating expenses | 2,211 | 2,302 | 4,439 | 4,141 |
| (Loss) income from operations | (1,867) | 2,447 | (2,233) | 6,674 |
| Interest income | 104 | 40 | 213 | 55 |
| Other income (expense), net | 14 | (13) | (34) | (26) |
| (Loss) income before income taxes | (1,749) | 2,474 | (2,054) | 6,703 |
| (Benefit from) provision for income taxes | (369) | 277 | (753) | 849 |
| Net (loss) income | $ (1,380) | $ 2,197 | $ (1,301) | $ 5,854 |
| (Loss) earnings per share: | ||||
| Basic (in usd per share) | $ (3.62) | $ 5.55 | $ (3.39) | $ 14.66 |
| Diluted (in usd per share) | $ (3.62) | $ 5.24 | $ (3.39) | $ 13.85 |
| Weighted average common shares used in calculation of (loss) earnings per share: | ||||
| Basic (in shares) | 381 | 396 | 383 | 399 |
| Diluted (in shares) | 381 | 419 | 383 | 423 |
| Product sales | ||||
| Revenue: | ||||
| Total revenue | $ 293 | $ 4,531 | $ 2,121 | $ 10,456 |
| Other revenue | ||||
| Revenue: | ||||
| Total revenue | $ 51 | $ 218 | $ 85 | $ 359 |
MRNA Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 3,801 | $ 3,205 |
| Investments | 4,658 | 6,697 |
| Accounts receivable | 232 | 1,385 |
| Inventory | 715 | 949 |
| Prepaid expenses and other current assets | 1,193 | 1,195 |
| Total current assets | 10,599 | 13,431 |
| Investments, non-current | 6,105 | 8,318 |
| Property, plant and equipment, net | 2,280 | 2,018 |
| Right-of-use assets, operating leases | 130 | 121 |
| Deferred tax assets | 1,480 | 982 |
| Other non-current assets | 1,290 | 988 |
| Total assets | 21,884 | 25,858 |
| Current liabilities: | ||
| Accounts payable | 310 | 487 |
| Accrued liabilities | 1,490 | 2,101 |
| Deferred revenue | 1,040 | 2,038 |
| Income taxes payable | 47 | 48 |
| Other current liabilities | 236 | 249 |
| Total current liabilities | 3,123 | 4,923 |
| Deferred revenue, non-current | 692 | 673 |
| Operating lease liabilities, non-current | 104 | 92 |
| Financing lease liabilities, non-current | 843 | 912 |
| Other non-current liabilities | 173 | 135 |
| Total liabilities | 4,935 | 6,735 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.0001; 162 shares authorized as of June 30, 2023 and December 31, 2022; no shares issued or outstanding at June 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, par value $0.0001; 1,600 shares authorized as of June 30, 2023 and December 31, 2022; 381 and 385 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 0 | 0 |
| Additional paid-in capital | 193 | 1,173 |
| Accumulated other comprehensive loss | (263) | (370) |
| Retained earnings | 17,019 | 18,320 |
| Total stockholders’ equity | 16,949 | 19,123 |
| Total liabilities and stockholders’ equity | $ 21,884 | $ 25,858 |
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics. The company has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.